BXP Q2 FFO $1.78, sales $895.7M beat analyst estimates
BXP Inc exceeded analyst estimates for Q2 2026 with FFO of $1.78/share and revenue of $895.699 million. Despite a drop in GAAP net income due to a Sumner Square impairment charge, core operational metrics improved, driving occupancy to 88.4%.

*this image is generated using AI for illustrative purposes only.
BXP, Inc., the largest publicly traded developer and manager of premier workplaces in the United States, reported second-quarter earnings that surpassed analyst expectations for both Funds from Operations (FFO) and revenue. The company posted diluted FFO of $1.78 per share, beating the consensus estimate of $1.70 by 4.71%. Total revenue for the quarter ended June 30, 2026, reached $895.699 million, exceeding the analyst estimate of $860.332 million by 4.11%.
The strong performance against estimates reinforces the company’s operational resilience. Revenue grew 3.14% year-over-year from $868.457 million in the prior year period, while FFO rose 4.09% from $1.71 per share in Q2 2025. Despite these positive indicators, GAAP net income attributable to BXP, Inc. decreased to $68.6 million, or $0.43 per diluted share, compared to $89.0 million, or $0.56 per diluted share, a year earlier. This decline was primarily driven by a $0.10 per diluted share non-cash impairment charge related to the anticipated disposition of Sumner Square in Washington, DC.
Leasing and Occupancy Trends
BXP executed 106 leases totaling approximately 1.8 million square feet in the second quarter, representing 129% of its historical 10-year average for the period. The weighted-average lease term was 9.9 years. Notable transactions included an approximately 148,000 square foot lease with McDermott Will & Schulte at 343 Madison Avenue in New York City, bringing the project’s pre-leased percentage to 50%, and an approximately 322,000 square foot lease with Boston Dynamics at Reservoir Place in Waltham, Massachusetts.
Total portfolio occupancy rose to 88.4%, an increase of 100 basis points from Q1 2026. Approximately 86% of this increase was driven by gains across the existing portfolio, while the remainder stemmed from the addition of the fully occupied 290 Binney Street property in Cambridge, Massachusetts, which was placed in-service in Q2 2026. The total portfolio leased percentage stood at 91.3%, up 40 basis points from the previous quarter.
Development and Balance Sheet Updates
In development news, BXP fully placed 290 Binney Street, a 572,578 square foot laboratory property in Cambridge, into service; it is 100% leased to AstraZeneca. The company also commenced redevelopment of Reservoir Place in Waltham, which is 89% pre-leased to Boston Dynamics. Additionally, BXP formed a joint venture with an institutional investor to develop a 359-unit multi-family residential project in Herndon, Virginia, holding a 20% ownership interest.
On July 28, 2026, BXP secured a $1.2 billion construction loan for the 343 Madison Avenue development in New York City. The loan features a four-year initial term with a one-year extension option and an initial interest rate of Term SOFR plus 2.50%, reducible to Term SOFR plus 2.25% upon achieving specific leasing and construction milestones.
What the Numbers Show
The divergence between BXP’s GAAP net income and its Funds from Operations highlights the impact of non-cash accounting items on reported profitability. While net income declined due to the Sumner Square impairment, the underlying operational cash flow, as proxied by FFO, strengthened. The ability to raise FFO guidance despite the impairment suggests that core rental income and expense management are outperforming earlier expectations, providing a buffer against one-time charges.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $895.7 million | $868.5 million | +3.1% |
| Net Income | $68.6 million | $89.0 million | Decrease |
| EPS (Diluted) | $0.43 | $0.56 | Decrease |
| FFO (Total) | $283.4 million | $271.7 million | Increase |
| FFO Per Share | $1.78 | $1.71 | Increase |
| Total Occupancy | 88.4% | Not Disclosed | +100 bps QoQ |
How will the $1.2 billion construction loan for 343 Madison Avenue impact BXP's leverage ratios and debt maturity profile over the next four years?
What are the long-term implications of BXP's strategic pivot toward life sciences and laboratory spaces, as evidenced by the fully leased 290 Binney Street and Reservoir Place projects?
Could the non-cash impairment charge on Sumner Square signal a broader trend of asset disposals or portfolio optimization in the Washington, DC market?

































